Accession Number:

ADA602848

Title:

Inherited Retinal Degenerative Disease Clinical Trial Network. Addendum

Descriptive Note:

Addendum to final rept. 30 Sep 2009-29 Sep 2010

Corporate Author:

NATIONAL NEUROVISION RESEARCH INST OWINGS MILLS MD

Personal Author(s):

Report Date:

2010-10-01

Pagination or Media Count:

66.0

Abstract:

The National Neurovision Research Institute NNRI, the clinical arm of the Foundation Fighting Blindness FFB, has established the National Eye Evaluation Research NEER Network composed of a collaborative group of five Clinical Treatment and Evaluation Centers CTECs and a support Clinical Coordinating Center. The intent of this new Network is to advance the science of therapeutic and preventive interventions for inherited orphan retinal degenerative diseases and dry age-related macular degeneration AMD through the conduct of clinical trials and other clinically relevant research. The scope of research to be carried out encompasses i Phase I and Phase II clinical trials to evaluate the safety and efficacy of new therapeutic and preventive approaches, including devices, biopharmaceuticals, small molecules, nutritional supplements, and gene transfer approaches natural history studies to develop standardized criteria to define disease stage, severity and progression iii observational studies to enhance understanding of the natural history of these diseases for different genotypes and phenotypes and iv evaluations of the reliability and validity of different available treatment outcomes measures to determine those that are most appropriate for various genotypes and phenotypes as well as for specific interventions. The NEER Network will also develop standard protocols for data collection, maintain and expand patient databases, classified by genotype and phenotype, to allow for the timely identification of eligible patients and facilitate patient access for clinical trial participation, and design and conduct, in collaboration with the Department of Defense, training programs for military ophthalmologists in the latest technologies and diagnostic and treatment regimens.

Subject Categories:

  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE